Latest Breaking News On - ஆறாவது சர்வதேச பணிமனை - Page 1 : comparemela.com
BeiGene Receives Positive CHMP Opinion for BRUKINSA (Zanubrutinib) for the Treatment of Adults with Waldenström s Macroglobulinemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström s Macroglobulinemia
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Posted on 422
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA
® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
“BRUKINSA is a highly selective BTK inhibitor designed to provide deep and durable response for patients with hematologic malignancies while reducing the frequency of certain side effects. With today’s approval, we are looking forward to bringing this potentially best-in-class BTK inhibitor to Canadians affected by WM,” said Josh Neiman, Chief Commercial Officer for North America and Europe at BeiGene. “We are committed to working to ensure access for patients in Canada and to making BRUKINSA available to patients in more markets worldwide.”
Press release content from Business Wire. The AP news staff was not involved in its creation.
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
March 2, 2021 GMT
CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Mar 2, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA ® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
“BRUKINSA is a highly selective BTK inhibitor designed to provide deep and durable response for patients with hematologic malignancies while reducing the frequency of certain side effects. With today’s approval, we are looking forward to bringing this potentially best-in-class BTK inhibitor to Canadians affected by WM,” said Josh Neiman, Chief Commercial Officer for North America and Euro